Can-Fite BioPharma Ltd. CANF
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-5.97
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $405.0K | $674.0K | $743.0K | $810.0K | $853.0K | $763.0K | $750.0K | $3.8M | $789.0K | $165.0K |
| R&D | $6.7M | $5.8M | $6.0M | $7.8M | $9.8M | $12.0M | $11.0M | $6.1M | $5.1M | $6.1M |
| SG&A | $3.7M | $3.0M | $3.0M | $3.1M | $3.8M | $317.0K | $3.1M | $3.2M | $2.9M | $2.7M |
| Total operating expenses | $10.4M | $8.8M | $8.9M | $10.9M | — | — | — | — | — | — |
| Operating income | -$9.9M | -$8.1M | -$8.2M | -$10.1M | -$12.8M | -$14.1M | -$12.0M | -$5.4M | -$7.2M | -$8.7M |
| Interest expense | $284.0K | $291.0K | $506.0K | $222.0K | $227.0K | $304.0K | $618.0K | $1.2M | — | — |
| Pre-tax income | -$9.8M | -$7.9M | -$7.6M | -$10.2M | -$12.6M | -$14.4M | -$12.6M | -$6.6M | -$4.8M | — |
| Income tax | — | — | — | — | — | — | — | $4.0K | $29.0K | — |
| Net income | -$9.8M | -$7.9M | -$7.6M | -$10.2M | -$12.6M | -$14.4M | -$12.6M | -$6.6M | -$4.8M | -$8.4M |
| EPS, basic | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 | -0.04 | — | — | — | — |
| EPS, diluted | -5.97 | -10.86 | -17.92 | -0.01 | -0.03 | -0.04 | -0.14 | -0.17 | -0.14 | — |
| Shares, diluted (wtd. avg.) | 1.6M | 725,309 | 426,111 | 815.7M | 553.1M | 358.4M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.5M | $4.8M | $4.3M | $3.0M | $4.4M | $8.3M | $2.7M | $3.6M | $3.5M | $8.1M |
| Short-term investments | $1.0K | $5.0K | $19.0K | $8.0K | $237.0K | $75.0K | $64.0K | — | — | — |
| Total current assets | $9.4M | $9.0M | $9.9M | $9.2M | $20.1M | $9.4M | $7.1M | $7.9M | — | — |
| Property, plant and equipment | $5.0K | $27.0K | $29.0K | $42.0K | $47.0K | $50.0K | $36.0K | $47.0K | — | — |
| Total assets | $9.5M | $9.1M | $10.0M | $9.3M | $20.3M | $9.5M | $8.2M | $8.0M | $7.6M | $10.2M |
| Accounts payable | $298.0K | $301.0K | — | — | — | — | — | — | — | — |
| Total current liabilities | $2.7M | $2.1M | $2.0M | $2.5M | $2.7M | $1.3M | $3.3M | $3.1M | — | — |
| Retained earnings | -$176.2M | -$166.4M | -$158.5M | -$150.8M | -$140.7M | -$125.5M | -$110.3M | -$97.7M | — | — |
| Total equity | $5.6M | $5.4M | $6.2M | $4.5M | $14.4M | $6.1M | $2.4M | $3.0M | $3.0M | $3.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.9M | -$7.6M | -$8.4M | -$10.8M | -$9.9M | -$12.1M | -$11.1M | -$4.2M | -$9.0M | — |
| Depreciation and amortisation | $24.0K | $7.0K | $15.0K | $14.0K | $14.0K | $12.0K | $14.0K | $14.0K | $19.0K | — |
| Stock-based compensation | $340.0K | $362.0K | $261.0K | $263.0K | $466.0K | $355.0K | $385.0K | $535.0K | $192.0K | — |
| Capital expenditure | $2.0K | $5.0K | $2.0K | $9.0K | $11.0K | $26.0K | $3.0K | $33.0K | $7.0K | — |
| Investing cash flow | -$2.0K | $1.5M | $498.0K | $9.5M | -$14.5M | -$26.0K | -$3.0K | -$33.0K | -$29.0K | — |
| Financing cash flow | $9.6M | $6.7M | $9.1M | — | $20.5M | $17.7M | $10.2M | $4.4M | $4.5M | — |
| Dividends paid | — | — | — | — | $2.6M | $715.0K | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-034447.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $165.0K | $789.0K | $3.8M | $750.0K | $763.0K | $853.0K | $810.0K | $743.0K | $674.0K | $405.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$8.4M | -$4.8M | -$6.6M | -$12.6M | -$14.4M | -$12.6M | -$10.2M | -$7.6M | -$7.9M | -$9.8M |
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |